Hepatitis C virus inhibitors

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein
• R2a and R2b are independently selected from hydrogen and methyl;
• R3 is selected from alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclyl, and heterocyclylalkyl;
• R4 is selected from —SR8, —S(O)—R8, and SO2R8;
• R6 is selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyloxycarbonyl, cycloalkyl, haloalkoxycarbonyl, haloalkyl, haloalkylcarbonyl, (NReRf)carbonyl, and (NReRf)sulfonyl;
• or
• R6 is selected from phenyl and a five- or six-membered partially or fully unsaturated ring optionally containing one, two, three, or four heteroatoms selected from nitrogen, oxygen, and sulfur;
• wherein each of the rings is optionally substituted with one, two, three, or four substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, carboxy, cyano, cycloalkyl, cycloalkyloxy, halo, haloalkyl, haloalkoxy, —NRgRh, (NRjRk)carbonyl, (NRjRk)sulfonyl, and oxo;
• R7 is selected from alkyl, cycloalkyl, and (cycloalkyl)alkyl;
• wherein the cycloalkyl and the cycloalkyl part of the (cycloalkyl)alkyl are optionally substituted with one group selected from alkenyl, alkoxy, alkyl, and halo;
• R8 is selected from alkoxyalkyl, alkyl, arylalkyl, haloalkoxyalkyl, and haloalkyl;
• and
• Q is a C5-7 saturated or unsaturated chain.